Unknown

Dataset Information

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.


ABSTRACT:

Background

The ongoing UNIFI long-term extension evaluates subcutaneous ustekinumab for moderate-to-severe ulcerative colitis (UC) from weeks 44 through 220.

Aims

To assess efficacy (through week 92) and safety (through week 96) during the long-term extension METHODS: Overall, 399 responders to intravenous ustekinumab induction and who were randomised to maintenance therapy were treated in the long-term extension (115 received subcutaneous placebo, 141 received ustekinumab 90 mg every 12 weeks [q12w], and 143 received ustekinumab 90 mg q8w). Placebo treatment was discontinued at unblinding after week 44. Partial Mayo scores were collected every 12 weeks and at each dosing visit after unblinding. Safety was evaluated throughout.

Results

Among all patients randomised in

SUBMITTER: Panaccione R 

PROVIDER: S-EPMC8776399 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature